NTD ConnectOR ~ Advanced search
To compare skin snip microfiladermia with antibody responses against Ov16 antigen in general population in epidemiological assessments post CDTi.
Field evaluation of two schistosome antibody-based rapid tests at point-of-care for prevalence mapping of urinary schistosomiasis in The Gambia
CCA Protocol: To know the sensitivity and specificity of POC CCA in the detection of urinary schistosomiasis, as compared to traditional diagnostic tools.
Field validation of sampling strategies for integrating STH surveys into Transmission Assessment Surveys (Ghana)
Test STH-TAS,Understand the age prevalence of LF Antibody in different setting.
SCORE Data Collection on Mobile Devises
Snail Control follow-up study of P. clarkii 20 years later
Human Diagnostics Tool Development (CAA diagnostic tool)
POC/CCA screening/mapping tool initial Studies
Screening Tool POC/CCA: PCR comparative studies
POC/CCA tool ongoing studies: Use of testing standards; reader differences; ‘Trace’ result analyses
Cost Studies in SCORE Gaining and Sustaining
Mapping of schistosomiasis (Sm)
Develop genetic markers for S. haematobium
Schistosome Population Genetics in Gaining Control Studies in Niger (Sh) and Tanzania (Sm)
Part of gaining control studies
Gaining Control: >25% Prevalence MDA strategies; and subtle morbidity of Cohort; Population genetics, and snail monitoring
Sustaining / Gaining Control with Single versus Double Treatment; and Population genetics, snail monitoring
MDA strategies: Sustaining control at 10 – 24% prevalence
(1) Is it possible to eliminate schistosomiasis as a public health problem on Unguja in three years and to interrupt transmission in five years? (2) Is it possible to control schistosomiasis throughout Pemba (prevalence <10%) in three years and to eliminate it as a public health problem in five years? (3) What are the costs, successful strategies, barriers, etc. associated with three different interventions (MDA, vector control, and behavior change)?
Randomized clinical trail comparing treatment with Albendazole and Ivermectin to Ivermectin alone for Onchocerciasis.
Randomized Clinical Trial of Albendazole vs Ivermectin+Albendazole for lymphatic filariasis treatment and elimination.
Randomized Clinical Trial comparing triple triple therapy of DEC/Alb/Iver vs. DEC/Alb alone
Comparison of 2X vs. 1X per year MDA on Brugia with MDA of DEC/Alb , plus STH evaluation
Community MDA with 2X Alb alone for W. bancrofti in areas co-endemic for L. loa, plus STH evaluation
Binax Now Filariasis Test vs. Alere Filariasis Test Strip Comparison
Comparison of 2X vs. 1X per year MDA on W. bancrofti with MDA of IVM/Alb, plus STH evaluation (and Schistosoma in Foya only)
Comparison of 2X vs. 1X per year MDA, W. bancrofti with MDA of DEC/Alb, plus STH evaluation